MC225A7 - 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha - Google Patents

2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha

Info

Publication number
MC225A7
MC225A7 MC225K MC225K MC225A7 MC 225 A7 MC225 A7 MC 225A7 MC 225 K MC225 K MC 225K MC 225 K MC225 K MC 225K MC 225 A7 MC225 A7 MC 225A7
Authority
MC
Monaco
Prior art keywords
carbon atoms
hydrogen
alkyl
dioxopiperidin
indolines
Prior art date
Application number
MC225K
Other languages
English (en)
French (fr)
Inventor
Roger Shen-Chu Chen
David I Stirling
George W Muller
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MC225A7 publication Critical patent/MC225A7/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MC225K 1997-05-30 2005-08-11 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha MC225A7 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4827897P 1997-05-30 1997-05-30

Publications (1)

Publication Number Publication Date
MC225A7 true MC225A7 (fr) 2006-03-07

Family

ID=21953674

Family Applications (1)

Application Number Title Priority Date Filing Date
MC225K MC225A7 (fr) 1997-05-30 2005-08-11 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha

Country Status (25)

Country Link
US (3) US6395754B1 (cs)
EP (3) EP0984955B1 (cs)
JP (2) JP4307567B2 (cs)
KR (1) KR100526212B1 (cs)
CN (3) CN1258293A (cs)
AT (2) ATE275139T1 (cs)
AU (1) AU741982B2 (cs)
CA (2) CA2291218C (cs)
CY (1) CY1108348T1 (cs)
CZ (1) CZ299812B6 (cs)
DE (2) DE69839739D1 (cs)
DK (2) DK0984955T3 (cs)
ES (3) ES2229497T3 (cs)
FI (1) FI19992490A (cs)
HK (1) HK1072248A1 (cs)
HU (2) HU228769B1 (cs)
MC (1) MC225A7 (cs)
NO (6) NO322080B1 (cs)
NZ (1) NZ501429A (cs)
PL (1) PL193276B1 (cs)
PT (2) PT1486496E (cs)
RU (1) RU2209207C2 (cs)
SK (1) SK163099A3 (cs)
TR (4) TR201005282T2 (cs)
WO (1) WO1998054170A1 (cs)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
ATE233753T1 (de) * 1997-11-18 2003-03-15 Celgene Corp Substituierte 2-(2,6-dioxo-3-fluoropiperidin-3- yl)-isoindoline und ihre verwendung zur verminderung des tnfa spiegels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101500T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
DE60023123T2 (de) 1999-03-18 2006-06-22 Celgene Corp. Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
DK1353672T3 (da) * 2000-11-30 2008-01-21 Childrens Medical Center Syntese af 4-amino-thalidomidenantiomerer
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2003086373A1 (en) * 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
MXPA04011311A (es) 2002-05-17 2005-02-14 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y el manejo de canceres y otras enfermedades.
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
IL165258A0 (en) * 2002-05-17 2005-12-18 Celgene Corp Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7842691B2 (en) * 2002-10-15 2010-11-30 Celgene Corporation Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
AU2003286663B2 (en) * 2002-10-24 2009-08-13 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
WO2004041190A2 (en) * 2002-10-31 2004-05-21 Celgene Corporation Composition for the treatment of macular degenration
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
BR0316057A (pt) 2002-11-06 2005-09-20 Celgene Corp Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
WO2004054501A2 (en) * 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
OA13284A (en) * 2003-11-06 2007-01-31 Corporation Celgene Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
EP2065383A1 (en) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazole compounds and methods of use thereof as protein kinase inhibitors
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
BRPI0418743A (pt) * 2004-04-14 2007-09-18 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BRPI0418742A (pt) * 2004-04-14 2007-09-11 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
MXPA06012278A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
JP2007536223A (ja) * 2004-05-05 2007-12-13 セルジーン・コーポレーション 骨髄増殖性疾患の治療及び管理のための免疫調節化合物を含む組成物、及びその使用方法
EP2479172B1 (en) * 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
MX2007005040A (es) * 2004-10-28 2007-06-19 Celgene Corp Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
CA2588597A1 (en) * 2004-11-23 2006-06-01 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
EP1848433A2 (en) * 2005-01-25 2007-10-31 Celgene Corporation Methods and compositions using 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
CN100383139C (zh) 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
ES2430545T3 (es) 2005-06-30 2013-11-21 Celgene Corporation Procedimientos para la preparación de compuestos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
JP2008544818A (ja) * 2005-06-30 2008-12-11 アントフロゲネシス コーポレーション 胎盤由来コラーゲンバイオ線維を用いた鼓膜の修復
EP1919500A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Treatment of leg ulcers using placenta derived collagen biofabric
WO2007009061A2 (en) * 2005-07-13 2007-01-18 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
CA2621136C (en) 2005-09-01 2014-10-14 Celgene Corporation Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
WO2007047468A2 (en) 2005-10-13 2007-04-26 Anthrogenesis Corporation Immunomodulation using placental stem cells
CN101374941A (zh) * 2005-12-29 2009-02-25 人类起源公司 采集和保存胎盘干细胞的改良组合物及其使用方法
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
WO2008021391A1 (en) 2006-08-15 2008-02-21 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
CA2660806C (en) * 2006-08-30 2015-06-16 Celgene Corporation 5-substituted isoindoline compounds
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
RU2448101C2 (ru) * 2006-08-30 2012-04-20 Селджин Корпорейшн 5-замещенные изоиндолиновые соединения
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
WO2008042441A1 (en) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Use of umbilical cord biomaterial for ocular surgery
WO2008060377A2 (en) 2006-10-04 2008-05-22 Anthrogenesis Corporation Placental or umbilical cord tissue compositions
JP5769925B2 (ja) 2006-10-06 2015-08-26 アントフロゲネシス コーポレーション ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法
CN101186611B (zh) 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
MX349225B (es) 2007-02-12 2017-07-19 Anthrogenesis Corp Uso de celulas madre placentarias para preparar medicamentos utiles en el tratamiento de padecimientos inflamatorios.
CA2677679A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
MY157495A (en) 2007-09-26 2016-06-15 Celgene Corp 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
KR20210022148A (ko) 2007-09-28 2021-03-02 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
WO2009085234A2 (en) 2007-12-20 2009-07-09 Signal Pharmaceuticals, Inc. Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
KR101696938B1 (ko) * 2008-10-29 2017-01-16 셀진 코포레이션 암의 치료에 사용하기 위한 이소인돌린 화합물
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
RU2742171C2 (ru) 2009-03-25 2021-02-02 Антродженезис Корпорейшн Супрессия опухолей с использованием полученных из плаценты человека промежуточных естественных киллерных клеток и иммуномодулирующих соединений
AU2010249615B2 (en) 2009-05-19 2013-07-18 Celgene Corporation Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
WO2011079091A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
CA2786266A1 (en) 2010-01-05 2011-07-14 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
SI3202461T1 (sl) 2010-02-11 2019-05-31 Celgene Corporation Derivati arilmetoksi izoindolina in sestavki, ki jih vsebujejo in metode uporabe le teh
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
US20140031325A1 (en) 2010-12-06 2014-01-30 Celgene Corporation Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
WO2012092485A1 (en) 2010-12-31 2012-07-05 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory rna molecules
EP2663549B1 (en) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP2014517915A (ja) 2011-04-18 2014-07-24 セルジーン コーポレイション 多発性骨髄腫治療のためのバイオマーカー
MX353482B (es) 2011-04-29 2018-01-16 Celgene Corp Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
AU2012308663B2 (en) 2011-09-14 2017-06-08 Amgen (Europe) GmbH Formulations of cyclopropanecarboxylic acid {2-[(1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide
AU2012362562B2 (en) 2011-12-27 2017-11-02 Amgen (Europe) GmbH Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
EP3967323A3 (en) 2012-06-06 2022-05-04 Bionor Immuno AS Hiv vaccine
CA3136093A1 (en) 2012-06-29 2014-01-03 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
US9133161B2 (en) 2012-07-27 2015-09-15 Celgene Corporation Processes for preparing isoindoline-1,3-dione compounds
ES2885769T3 (es) 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
SG11201501653RA (en) 2012-09-10 2015-04-29 Celgene Corp Methods for the treatment of locally advanced breast cancer
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
WO2014152833A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US20140314752A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
SI3182996T1 (sl) 2014-08-22 2023-04-28 Celgene Corporation Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
KR102191256B1 (ko) 2014-10-30 2020-12-15 강푸 바이오파마슈티칼즈 리미티드 이소인돌린 유도체, 이의 중간체, 제조방법, 약물 조성물 및 응용
HUE065109T2 (hu) 2015-06-26 2024-05-28 Celgene Corp Eljárások Kaposi-szarkóma vagy KSHV-indukált limfóma kezelésére immunomodulátor vegyületek alkalmazásával, valamint biomarkerek alkalmazása
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
ITUB20169994A1 (it) 2016-01-14 2017-07-14 Phf Sa Nuove forme cristalline di farmaci immunomodulatori
CN110248678A (zh) 2016-12-03 2019-09-17 朱诺治疗学股份有限公司 调节car-t细胞的方法
PT3618842T (pt) 2017-05-01 2024-01-12 Juno Therapeutics Inc Combinação de uma terapia celular e de um composto imunomodulador
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
US20200246393A1 (en) 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
WO2019089969A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3755718A1 (en) 2018-02-21 2020-12-30 Celgene Corporation Bcma-binding antibodies and uses thereof
WO2019191112A1 (en) 2018-03-26 2019-10-03 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
WO2019204354A1 (en) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Spirocyclic compounds
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2020051235A1 (en) 2018-09-04 2020-03-12 C4 Therapeutics, Inc. Compounds for the degradation of brd9 or mth1
AU2019377854A1 (en) 2018-11-08 2021-05-27 Juno Therapeutics, Inc. Methods and combinations for treatment and T cell modulation
AU2019381688A1 (en) 2018-11-13 2021-06-03 Biotheryx, Inc. Substituted isoindolinones
WO2020102770A1 (en) 2018-11-16 2020-05-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
JP2022518925A (ja) 2019-01-29 2022-03-17 ジュノー セラピューティクス インコーポレイテッド 受容体チロシンキナーゼ様オーファン受容体１（ｒｏｒ１）に特異的な抗体およびキメラ抗原受容体
EP3935050B1 (en) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023250400A1 (en) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590189A (en) * 1982-04-02 1986-05-20 Takeda Chemical Industries, Ltd. Condensed pyrrolinone derivatives, their production and use
CA1284647C (en) * 1986-12-25 1991-06-04 Kazuhiro Kubo Isoindolin-1-one derivative and anti-arrhythmic agent
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
WO1992014455A1 (en) * 1991-02-14 1992-09-03 The Rockefeller University METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES
DE4211812C2 (de) * 1991-04-17 1994-05-05 Gruenenthal Gmbh Thalidomidderivate, ein Verfahren zu deren Herstellung sowie die Verwendung derselben in Arzneimitteln
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
DE4422237A1 (de) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5795368A (en) * 1996-03-01 1998-08-18 O.I. Corporation Microtrap sample concentrator and methods of use
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
CZ304569B6 (cs) * 1996-07-24 2014-07-09 Celgene Corporation 1,3-Dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin pro použití pro snížení nežádoucí hladiny TNFα u savce
CZ299810B6 (cs) * 1996-08-12 2008-12-03 Celgene Corporation Substituovaná aromatická sloucenina a její použití pro snížení hladiny cytokinu
JP2002513391A (ja) * 1996-11-05 2002-05-08 ザ チルドレンズ メディカル センター コーポレイション 血管形成の抑制のための方法と組成物
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101500T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il)izoindolin türevleri, bunların hazırlanması ve enflamatuarn sitokinlerin inhibitörleri olarak kullanımı.
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
NZ514711A (en) * 1999-03-12 2004-02-27 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
DE60023123T2 (de) * 1999-03-18 2006-06-22 Celgene Corp. Substituierte 1-oxo- und 1,3-dioxoisoindoline und ihre verwendung in pharmazeutischen zusammensetzungen zur senkung des spiegels inflammatorisch wirkender cytokine
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
AU2001249755A1 (en) * 2000-03-31 2001-10-15 Celgene Corporation Inhibition of cyclooxygenase-2 activity
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
DK1353672T3 (da) 2000-11-30 2008-01-21 Childrens Medical Center Syntese af 4-amino-thalidomidenantiomerer
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
JP4361273B2 (ja) * 2001-02-27 2009-11-11 アメリカ合衆国 潜在的な血管形成阻害剤としてのサリドマイド類似体
ATE428419T1 (de) 2001-08-06 2009-05-15 Childrens Medical Center Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
WO2003086373A1 (en) 2002-04-12 2003-10-23 Celgene Corporation Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
MXPA04011311A (es) 2002-05-17 2005-02-14 Celgene Corp Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y el manejo de canceres y otras enfermedades.
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
AU2003286663B2 (en) 2002-10-24 2009-08-13 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2004041190A2 (en) 2002-10-31 2004-05-21 Celgene Corporation Composition for the treatment of macular degenration
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
AU2004296765B2 (en) * 2003-12-02 2011-03-24 Celgene Corporation Methods and compositions for the treatment and management of hemoglobinopathy and anemia
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
AU2005226649B2 (en) 2004-03-22 2010-04-29 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
BRPI0418742A (pt) 2004-04-14 2007-09-11 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
MXPA06012278A (es) 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de la hipertension pulmonar.
JP2007536223A (ja) 2004-05-05 2007-12-13 セルジーン・コーポレーション 骨髄増殖性疾患の治療及び管理のための免疫調節化合物を含む組成物、及びその使用方法

Also Published As

Publication number Publication date
CA2291218A1 (en) 1998-12-03
ATE401319T1 (de) 2008-08-15
CY1108348T1 (el) 2014-02-12
NO333641B1 (no) 2013-07-29
AU741982B2 (en) 2001-12-13
NO995751D0 (no) 1999-11-23
EP1956017B1 (en) 2013-01-23
NO995751L (no) 2000-01-28
NO20120330L (no) 2000-01-28
EP0984955A1 (en) 2000-03-15
CZ427899A3 (cs) 2000-05-17
ES2229497T3 (es) 2005-04-16
US6395754B1 (en) 2002-05-28
CA2669481A1 (en) 1998-12-03
TR200000107T2 (tr) 2000-07-21
CN1680367A (zh) 2005-10-12
HUP0003217A3 (en) 2002-03-28
TR200500299T2 (tr) 2005-06-21
NO322080B1 (no) 2006-08-14
DE69825994T2 (de) 2005-09-29
DE69839739D1 (de) 2008-08-28
NO331367B1 (no) 2011-12-12
AU7701298A (en) 1998-12-30
DE69825994D1 (de) 2004-10-07
NO20111536L (no) 2000-01-28
CN1258293A (zh) 2000-06-28
SK163099A3 (en) 2000-06-12
NO20061455L (no) 2000-01-28
PL337124A1 (en) 2000-07-31
DK0984955T3 (da) 2005-01-03
US20050131024A1 (en) 2005-06-16
ES2403102T3 (es) 2013-05-14
KR20010013097A (ko) 2001-02-26
EP1956017A1 (en) 2008-08-13
JP4307567B2 (ja) 2009-08-05
PT1486496E (pt) 2008-07-30
HUP9903929A3 (en) 2004-04-28
DK1486496T3 (da) 2008-09-08
JP2009138009A (ja) 2009-06-25
HK1072248A1 (en) 2005-08-19
ES2309443T3 (es) 2008-12-16
US20020173658A1 (en) 2002-11-21
HU229578B1 (en) 2014-02-28
CN1911927A (zh) 2007-02-14
PT984955E (pt) 2005-01-31
PL193276B1 (pl) 2007-01-31
EP1486496B1 (en) 2008-07-16
NO2012004I1 (no) 2012-03-19
FI19992490A (fi) 2000-01-27
HUP9903929A2 (hu) 2000-05-29
CA2291218C (en) 2009-10-13
RU2209207C2 (ru) 2003-07-27
TR200801878T2 (tr) 2008-08-21
NO2012004I2 (no) 2013-05-06
KR100526212B1 (ko) 2005-11-03
US7459466B2 (en) 2008-12-02
NO332270B1 (no) 2012-08-13
EP1486496A1 (en) 2004-12-15
CZ299812B6 (cs) 2008-12-03
TR201005282T2 (tr) 2011-06-21
CA2669481C (en) 2011-10-04
NO20092860L (no) 2000-01-28
WO1998054170A1 (en) 1998-12-03
EP0984955B1 (en) 2004-09-01
HU228769B1 (en) 2013-05-28
ATE275139T1 (de) 2004-09-15
NZ501429A (en) 2001-11-30
NO332271B1 (no) 2012-08-13
JP2002501536A (ja) 2002-01-15
HUP0003217A2 (hu) 2001-06-28

Similar Documents

Publication Publication Date Title
MC225A7 (fr) 2-(2,6-Dioxopiperidine-3-yl)-phtalimides et-1-oxo-iso-indolines substitutes et methodes pour reduireles taux de tnf-alpha
HK1049004A1 (zh) 含氮的環狀化合物和含有該化合物的藥用組合物
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
SE0000772D0 (sv) Chemical compounds
DE69332792T2 (de) 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
EP1447400A4 (en) BICYCLIC COMPOUND
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
AU633408B2 (en) New imidazo (1,2-c) derivatives, process for the preparation thereof and pharmaceutical compositions containing them
GR3031173T3 (en) 1,4-Dihydropyridine derivatives, process for their preparation and therapeutical composition containing them
DK0412058T3 (da) 1-Acyl-2-pyrrolidinoner som indlærings- og hukommelsesforstærkende midler og farmaceutiske præparater indeholdende disse forbindelser
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
TW350835B (en) Process for preparing nitroaniline derivatives
SE8800863D0 (sv) 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith
EP1120415A4 (en) SUBSTITUTED ISOXAZOLYLTHIOPHENE COMPOUNDS
MY133207A (en) Substituted benzolactam compaunds
RS51051B (sr) Heksaciklična jedinjenja
ATE66475T1 (de) Aromatische thioaether.
ATE500241T1 (de) Phenyl- und pyridyl-piperidine mit tnf-wirkung
ES2107376A1 (es) Nuevos derivados de pirimidona con actividad antifungica.